6月12日消息 - 环球医学据悉，现已发现一种可有效对抗阿尔茨海默氏症的新疫苗，为那些因该病而虚弱并遭遇复杂状况的患者带来希望。

阿尔茨海默氏症是由淀粉样前体蛋白（APP）引起的，APP是一种驻留在神经细胞外膜上的蛋白质，它没有被分解，而是形成一种被称为β-淀粉样蛋白的有害物质，该物质聚积成斑块并杀死脑细胞。

《柳叶刀神经病学》杂志报道说，以瑞典卡罗琳学院阿尔茨海默氏症研究中心Bengt Winblad教授为首的研究人员与顶尖的神经学家合作，发现试验中80％的患者产生了对抗β-淀粉样蛋白的自身保护性抗体，且在3年的研究期间没有出现任何副作用。

目前还没有办法治愈阿尔茨海默氏症，根据世界卫生组织统计，该病是全球增长最快的公共卫生危机，卡罗琳学院在一份声明中说，现在治疗该病的药物，充其量只能缓解症状。

为寻求治愈该病的方法，科学家们还正在探求疫苗接种。首例人类接种疫苗的研究大约是在10年前，该研究出现了太多的不良反应并因此而中断。该疫苗激活了某些白细胞（T细胞），后者可攻击人体自身的脑组织。

新的治疗包括应用CAD106疫苗进行主动免疫接种，该疫苗旨在引发人体的免疫系统对抗β-淀粉样蛋白。在这项第二次人类临床试验中，该疫苗已被修饰为仅仅对有害的β-淀粉样蛋白有作用。

研究人员认为，这表明CAD106疫苗是一种可耐受的治疗轻中度阿尔茨海默氏症患者的方法。现在需要进行更大规模的试验来证实CAD106疫苗的疗效。
（环球医学）

原文：

Potent New Vaccine Offers Hope for Alzheimer's Patients

A new vaccine has been found effective against Alzheimer's, bringing hopes for those suffering from the debilitating and complex conditions of the disease. 

Alzheimer's is caused by amyloid precursor protein (APP), a protein that resides in the outer membrane of nerve cells, which instead of being broken down, forms a harmful substance called beta-amyloid, accumulating as plaques and killing brain cells. 

Researchers led by Bengt Winblad, professor at Karolinska Institutet's Alzheimer's Disease Research Center in Sweden, working with leading neurologists, found that 80 percent of the patients in the trials developed their own protective antibodies against beta-amyloid without suffering any side-effects over the three years of the study, the journal Lancet Neurology reports. 

There is currently no cure for Alzheimer's disease, the fastest growing global health epidemic, according to the World Health Organization and the medicines in use can at best only mitigate symptoms, according to a Karolinska statement. 

In the hunt for a cure, scientists are also pursuing vaccination. The first human vaccination study, done almost a decade ago, revealed too many adverse reactions and was discontinued. That vaccine activated certain white blood cells (T cells), which attacked the body's own brain tissue. 

The new treatment involves active immunization, using a type of vaccine CAD106 designed to trigger the body's immune system against beta-amyloid. In this second clinical trial on humans, the vaccine was modified to affect only the harmful beta-amyloid. 

Researchers believe that this suggests that the CAD106 vaccine is a tolerable treatment for patients with mild to moderate Alzheimer's. Larger trials must now be conducted to confirm the CAD106 vaccine's efficacy.
 

相关链接：http://www.medindia.net/news/potent-new-vaccine-offers-hope-for-alzheimers-patients-102478-1.htm126.am/aQ40G3

版权声明：本文系环球医学独家稿件，版权为环球医学所有。欢迎转载，请务必注明出处（环球医学网），否则必将追究法律责任。